General Information of Drug (ID: DM8J29L)

Drug Name
Abrocitinib Drug Info
Synonyms PF-04965842
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Lupus 4A40 Phase 2 [2]
Cross-matching ID
PubChem CID
78323835
CAS Number
CAS 1622902-68-4
TTD Drug ID
DM8J29L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Baricitinib DM4ONW5 Rheumatoid arthritis FA20 Approved [4]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [5]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [6]
KD019 DMEFW3G Brain metastases 2D50 Phase 2 [6]
LEO 124249 DM7W0JE Asthma CA23 Phase 2 [3]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [3]
TD-1473 DMJG7AY Ulcerative colitis DD71 Phase 1 [5]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [7]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [7]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [1]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [1]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [1]
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [3]

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 213871.
2 ClinicalTrials.gov (NCT02201524) Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.